舒泰神(300204) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥65,017,235.12, a decrease of 47.29% compared to ¥123,340,760.08 in the same period last year[3] - The net loss attributable to shareholders was ¥48,725,047.50, representing a 99.62% increase in loss from ¥24,409,475.07 year-on-year[3] - The net cash flow from operating activities was -¥48,703,447.32, a decline of 31.99% compared to -¥36,899,357.21 in the previous year[3] - Operating income decreased by ¥58,323,524.96, a drop of 47.29%, mainly due to adverse effects from centralized procurement policies[8] - Sales expenses decreased by ¥19,975,150.89, a reduction of 40.10%, attributed to lower sales revenue[8] - Total operating revenue for Q1 2023 was ¥65,017,235.12, a decrease of 47.3% compared to ¥123,340,760.08 in the same period last year[28] - Total operating costs for Q1 2023 were ¥112,694,083.52, down 24.7% from ¥149,627,134.34 year-over-year[28] - Net loss for Q1 2023 was ¥48,725,047.50, compared to a net loss of ¥24,409,475.07 in Q1 2022, representing a 99.5% increase in losses[29] - The company reported a comprehensive loss of ¥78,828,739.97 for Q1 2023, compared to a comprehensive loss of ¥73,058,069.38 in Q1 2022[30] - Basic and diluted earnings per share for Q1 2023 were both -¥0.10, compared to -¥0.05 in the same quarter last year[30] Assets and Liabilities - Total assets decreased by 7.71% to ¥1,540,576,544.83 from ¥1,669,315,254.73 at the end of the previous year[4] - The company's current assets totaled CNY 447,292,083.04, down from CNY 529,058,099.35 at the start of the year, indicating a reduction of approximately 15.5%[25] - The company's cash and cash equivalents were CNY 212,005,194.21, compared to CNY 264,987,760.35 at the beginning of the year, reflecting a decrease of about 20%[25] - Total liabilities amounted to ¥265,242,801.64, a decrease from ¥315,452,471.57 year-over-year[29] - Total equity attributable to shareholders was ¥1,275,333,743.19, down from ¥1,353,862,783.16 in the previous year[29] - The company reported a total non-current asset value of CNY 1,093,284,461.79, down from CNY 1,140,257,155.38 at the beginning of the year[26] Cash Flow - Cash flow from operating activities showed a net outflow of ¥48,703,447.32, worsening from a net outflow of ¥36,899,357.21 in Q1 2022[31] - Cash inflow from investment activities was ¥13,541,351.26, significantly lower than ¥102,616,156.22 in the previous year[31] - The net cash flow from investment activities was 8,184,269.95 CNY, compared to 55,899,099.38 CNY in the same period last year[32] - The net cash flow from financing activities was -12,404,750.94 CNY, indicating a significant outflow compared to -611,439.43 CNY in the previous year[32] - The cash outflow from investment activities totaled 5,357,081.31 CNY in Q1 2023, compared to 46,717,056.84 CNY in the same quarter last year[32] - The cash inflow from financing activities was 688,720.00 CNY, with cash outflow totaling 13,093,470.94 CNY in Q1 2023[32] - The net increase in cash and cash equivalents for Q1 2023 was -52,982,566.14 CNY, contrasting with an increase of 18,306,773.64 CNY in the previous year[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,084[13] - The largest shareholder, Yizhao (Beijing) Pharmaceutical Technology Co., Ltd., holds 36.30% of shares, totaling 172,532,363 shares[13] - The second-largest shareholder, Xiangtang Group Co., Ltd., holds 9.06% of shares, totaling 43,082,186 shares, with 41,472,708 shares pledged[13] - The total number of restricted shares held by executives at the end of the period is 5,798,871 shares[15] - The company’s major shareholders include various asset management plans and individual investors, indicating a diverse ownership structure[14] Clinical Trials and Product Development - The company has completed the first patient dosing for the Phase II clinical trial of STSP-0601 for hemophilia A or B patients[17] - The Phase I clinical trial results for STSA-1002 indicate good safety and tolerability, with a significant reduction in C5a levels post-administration[18] - The company reported a trend of improved healing rates for diabetic foot ulcers when using Su Taisheng in conjunction with standard treatment[17] - The company has received approval for multiple new indications for its products, enhancing its clinical pipeline[17][18] - The company is actively expanding its clinical research and product development efforts, focusing on innovative therapies[17][18] - The company announced the initiation of the Ib/II clinical trial for the gene drug "STSG-0002 injection" targeting chronic hepatitis B virus infection, with the trial focusing on safety and efficacy[19] - The company received approval from the National Medical Products Administration for the clinical trial of "STSA-1002 injection" for acute respiratory distress syndrome (ARDS)[20] - The company's subsidiary InflaRx obtained FDA Emergency Use Authorization (EUA) for the drug Gohibic (Vilobelimab) to treat COVID-19 in hospitalized adults[20] Compliance and Regulatory - The company passed the GMP compliance inspection for its oral solution production line, confirming adherence to the 2020 revised Drug Production Quality Management Standards[21] - The company is in the process of issuing shares to specific investors, with the application accepted by the Shenzhen Stock Exchange[19] Miscellaneous - The company reported a negative impact of -58,637.83 CNY from exchange rate fluctuations on cash and cash equivalents[32] - The company’s first-quarter report for 2023 was not audited[33]